New Chroma Medicine board member Jeff Marrazzo

Jeff Mar­raz­zo has found a buzzy new biotech cause to cham­pi­on. And once again, he's all in

Jeff Mar­raz­zo is one of those biotech ex­ecs who has al­ways been fo­cused on the next big goal. He has a track record for meet­ing ob­jec­tives, re­lent­less­ly stay­ing on mes­sage, and break­ing new ground.

The fact that he stayed around for a cou­ple of years af­ter Roche’s $4.3 bil­lion Spark buy­out, mak­ing sure the or­ga­ni­za­tion he found­ed weath­ered Covid-19, is one ex­am­ple. And that came af­ter he care­ful­ly guid­ed the com­pa­ny to the first-ever US ap­proval of a gene ther­a­py — no easy task.

Endpoints Premium

This article is for premium subscribers only

Upgrade to a premium subscription plan for unlimited access, and join our community of key biopharma players.